Patents Examined by Paul Martin
-
Patent number: 10006840Abstract: The present invention provides methods and compositions for separating cells from a sample containing erythrocytes. The method is for recovering desired cells from a sample containing the desired cells, erythrocytes and undesired cells comprising: a) contacting the sample with a composition, said composition comprising: i) an erythrocytes aggregation reagent ii) at least one antigen recognizing moiety coupled to a magnetic particle, wherein said particle with said at least one antigen recognizing moiety specifically binds to at least one antigen specific for one or more undesired cellular components; b) applying simultaneously i) gravity sedimentation for sedimentation of erythrocytes and ii) a magnetic field gradient to said sample for immobilizing said magnetic particle generating a pellet and a supernatant phase, and c) recovering the desired cells from the supernatant phase. Compositions for the use within the present method are also disclosed.Type: GrantFiled: November 20, 2012Date of Patent: June 26, 2018Assignee: Miltenyi Biotec GmbHInventors: Burgund Kauling, Volker Huppert
-
Patent number: 9958432Abstract: The invention relates to systems and methods for studying patient cancer samples in cis-co-culture with stromal cells from the same patient. For example, the invention provide systems and methods for testing therapeutic agents in vitro in an environment that simulates an in vivo environment to identify agents that are therapeutically effective for the patient.Type: GrantFiled: September 19, 2014Date of Patent: May 1, 2018Assignee: LYNX BIOSCIENCES, INC.Inventors: Chorom Pak, Edmond Wai Keung Young, Natalie Callander, David James Beebe, Shigeki Miyamoto
-
Patent number: 9931381Abstract: Physiologically acceptable anti-biofilm compositions comprising Serratia peptidase and optionally one or more of bromelain, papain and a fibrinolytic enzyme. Additional components can include antimicrobials, antibiotics, antifungals, herbals, chelating agents, lactoferrin and related compounds, minerals, surfactants, binders, and fillers useful for the inhibition and treatment of gastrointestinal biofilms in humans. Physiologically acceptable anti-biofilm compositions containing these enzymes are useful in the inhibition, reduction and/or treatment of biofilms such as in the ear, vagina, joints, bones, gut, surgical sites and other locations, and are useful for the inhibition, reduction and/or treatment of associated systemic symptoms caused by biofilm associated microorganisms.Type: GrantFiled: November 23, 2010Date of Patent: April 3, 2018Assignee: PROTHERA, INC.Inventor: Stephen Francis Olmstead
-
Patent number: 9920344Abstract: The present invention relates to a method for producing a composition containing isomaltulose from a substrate containing sucrose comprising the steps of: a) contacting the substrate containing sucrose with a particulate carrier-immobilized sucrose isomerase biomass and b) obtaining a composition containing isomaltulose, characterized in that the median particle size d(0.5) of the carrier-immobilized sucrose isomerase biomass is from 370 to 550 ?m. The carrier can be an alginate or a polyvinyl alcohol carrier.Type: GrantFiled: July 17, 2014Date of Patent: March 20, 2018Assignee: SÜDZUCKER AKTIENGESELLSCHAFT MANNHEIM/OCHSENFURTInventors: Wolfgang Wach, Thomas Rose
-
Patent number: 9909158Abstract: A method of producing a sugar liquid from a cellulose-containing biomass includes (1) hydrolyzing a cellulose-containing biomass using a filamentous fungus-derived cellulose and carrying out solid-liquid separation into a sugar liquid and a hydrolysis residue; (2) washing the hydrolysis residue in (1) using an aqueous alkaline solution and an aqueous inorganic salt solution independently and recovering, as a washing liquid, the filamentous fungus-derived cellulase adsorbed to the hydrolysis residue; and (3) filtering the washing liquid in (2) through an ultrafiltration membrane to recover a sugar liquid as a permeate and the filamentous fungus-derived cellulase as a non-permeate.Type: GrantFiled: July 1, 2013Date of Patent: March 6, 2018Assignee: Toray Industries, Inc.Inventors: Chiaki Yamada, Hiroyuki Kurihara, Katsushige Yamada
-
Patent number: 9878070Abstract: Provided is a malleable implant configured to fit at or near a bone defect site to promote bone growth, the malleable implant comprising: a biodegradable polymer, mineral particles, and an oxysterol, the implant configured to become moldable upon being wetted with a fluid. Methods of making and use are further provided.Type: GrantFiled: June 17, 2015Date of Patent: January 30, 2018Inventors: Benjamin T. Reves, David S. Scher, Susan J. Drapeau, Roger E. Harrington, Jerbrena C. Jacobs
-
Patent number: 9879304Abstract: The present invention provides a method of quantifying the activity of a protein modifying enzyme in a sample, comprising: (i) grouping modified peptides from a first sample and modified peptides from a second sample into a single group according to one of the following parameters: (a) modified peptides having a modification site that is modified by the same protein modifying enzyme; or (b) modified peptides having a modification site that is part of the same modification motif; (ii) calculating enrichment of the modified peptides from the first sample compared to the modified peptides from the second sample in the group; and (iii) calculating the statistical significance of said enrichment; wherein a statistically significant enrichment is indicative of a protein modifying enzyme being activated in the first sample compared to the second sample. In some embodiments, the method further comprises identifying modified peptides in a first sample and a second sample using mass spectrometry (MS) prior to step (i).Type: GrantFiled: March 8, 2013Date of Patent: January 30, 2018Assignee: Queen Mary & Westfield College, University of LondonInventor: Pedro Rodriguez Cutillas
-
Patent number: 9872502Abstract: The present invention relates to fungi of Acremonium spp, wherein said fungi are purified or isolated from plants of the Brachiaria-Urochloa complex and wherein, when said fungi are inoculated into a plant, said plant has improved resistance to diseases and/or pests relative to an uninocualated control plant. The present invention also relates to plants inoculated with such fungi, products produced by the fungi and related genes, proteins and methods.Type: GrantFiled: June 1, 2012Date of Patent: January 23, 2018Assignee: Agriculture Victoria Services Pty LtdInventors: German Carlos Spangenberg, Kathryn Michaela Guthridge
-
Patent number: 9862980Abstract: The present invention provides a process for enzyme mediated hydrolysis of biomass for production of soluble sugars, wherein the said process comprises of steady addition of small portions of biomass to enzyme solution, enabling rapid solubilization of biomass. The process used for enzymatic saccharification allows for increased biomass loading, enzyme recycle and mitigation of substrate and product inhibitory effect. The recycling of unhydrolysed biomass along with soluble enzyme ensures complete reuse of the said enzyme for effective repeated hydrolysis thereby increasing the overall productivity of enzyme used.Type: GrantFiled: January 16, 2015Date of Patent: January 9, 2018Assignees: Department of Biotechnology, Institute of Chemical TechnologyInventors: Arvind Mallinath Lali, Annamma Anil Odaneth, Sachinkumar Hiraman Birhade, Juliet Joanna Victoria, Sneha Chandrakant Sawant
-
Patent number: 9857359Abstract: Use of cereblon-associated proteins as biomarkers for clinical sensitivity to cancer, inflammatory diseases, and patient response to drug treatment.Type: GrantFiled: June 28, 2013Date of Patent: January 2, 2018Assignee: CELGENE CORPORATIONInventors: Peter H. Schafer, Rajesh Chopra, Antonia Lopez-Girona, Laura Corral, Maria Yinglin Wang, Pilgrim Jackson
-
Patent number: 9855305Abstract: The present invention relates to a pharmaceutical composition containing a combination of vitamins, specific salts of calcium, magnesium, and iron, probiotics and prebiotics, which prevents the occurrence of adverse effects associated with long-term use of proton-pump inhibitors (PPIs). This effect is achieved by restoring all nutrient deficiencies and rectifying the intestinal flora imbalance caused by this type of drugs, particularly in patients with gastroesophageal reflux disease and Zollinger-Ellison syndrome.Type: GrantFiled: March 29, 2016Date of Patent: January 2, 2018Assignee: Companion Therapeutics LLCInventors: Julio César Villamil Torres, Camilo Rey Ferro
-
Patent number: 9857387Abstract: The invention provides a method of detecting abnormal entry of gastrointestinal contents into the respiratory tract of a patient. The method comprises orally administering to a subject formulation comprising a detectable label that is not absorbed from the gastrointestinal tract but can be absorbed from the respiratory tract. The extent of the gastrointestinal contents entering the respiratory tract can be estimated by measuring the level of the detectable label in a body fluid, e.g., blood or urine.Type: GrantFiled: February 18, 2015Date of Patent: January 2, 2018Assignees: Aradigm Corporation, The Regents of The University of CaliforniaInventors: Igor Gonda, Homer A. Boushey
-
Patent number: 9850504Abstract: Described is a method for the production of 3-buten-2-one comprising the enzymatic conversion of 4-hydroxy-2-butanone into 3-buten-2-one by making use of an enzyme catalyzing 4-hydroxy-2-butanone dehydration, wherein said enzyme catalyzing 4-hydroxy-2-butanone dehydration is (a) a 3-hydroxypropiony-CoA dehydratase (EC 4.2.1.116), (b) a 3-hydroxybutyryl-CoA dehydratase (EC 4.2.1.55), (c) an enoyl-CoA hydratase (EC 4.2.1.17), (d) a 3-hydroxyoctanoyl-[acyl-carrier-protein] dehydratase (EC 4.2.1.59), (e) a crotonyl-[acyl-carrier-protein] hydratase (EC 4.2.1.58), (f) a 3-hydroxydecanoyl-[acyl-carrier-protein] dehydratase (EC 4.2.1.60), (g) a 3-hydroxypalmitoyl-[acyl-carrier-protein] dehydratase (EC 4.2.1.61), (h) a long-chain-enoyl-CoA hydratase (EC 4.2.1.74), or (i) a 3-methylglutaconyl-CoA hydratase (EC 4.2.1.18). The produced 3-buten-2-one can be further converted into 3-buten-2-ol and finally into 1,3-butadiene.Type: GrantFiled: July 2, 2014Date of Patent: December 26, 2017Assignees: Scientist of Fortune, S.A., Global BioenergiesInventors: Philippe Marliere, Maria Anissimova, Mathieu Allard
-
Patent number: 9840727Abstract: Methods are provided for the prognosis, diagnosis and treatment of various pathological states, including cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. The methods provided herein are based on the discovery that various proteins with a high level of sialylation are shown herein to be associated with disease states, such as, cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. Such methods provide a lysosomal exocytosis activity profile comprising one or more values representing lysosomal exocytosis activity. Also provided herein, is the discovery that low lysosomal sialidase activity is associated with various pathological states. Thus, the methods also provide a lysosomal sialidase activity profile, comprising one or more values representing lysosomal sialidase activity. A lysosomal sialidase activity profile is one example of a lysosomal exocytosis activity profile.Type: GrantFiled: June 20, 2016Date of Patent: December 12, 2017Assignee: St. Jude Children's Research HospitalInventors: Ida Annunziata, Alessandra D'Azzo, Shai White-Gilbertson
-
Patent number: 9835614Abstract: System and Method for measuring the growth of a bacterial culture and its response to one or more antimicrobials using measurement of mass of individual microbes. Methods include periodic sampling, determining change in mass and concentration, and comparing growth rates of cultures in nutrient broth vs. mixtures containing various antibiotic mixtures. A number of antimicrobials can be compared in one measurement by multiplexing or using multiple sensors to measure in parallel. Growth and antibiotic efficacy can be assessed at low concentrations at the onset of growth, typically within 1 to 2 hours.Type: GrantFiled: September 8, 2014Date of Patent: December 5, 2017Assignee: Affinity Biosensors, LLCInventors: Ken Babcock, Cynthia Schneider
-
Patent number: 9791456Abstract: The present relates to methods for detecting DNA damage in subjects treated with an ATR inhibitor. More specifically, this invention relates to a method for measuring changes in levels of ?H2AX and/or pChk1Ser345 in, e.g., surrogate tissue cells, following ex vivo stimulation with a DNA damaging agent.Type: GrantFiled: February 27, 2015Date of Patent: October 17, 2017Assignees: Vertex Pharmaceuticals Incorporated, University of Newcastle Upon TyneInventors: Susanna Falcon, Philip Reaper, John Pollard, Nicola Curtin, Fiona Middleton, Tao Chen
-
Patent number: 9763969Abstract: The present invention describes compositions and related methods and kits for treating a variety of inflammatory conditions and infections. The therapeutic compositions include certain hyaluronidases capable of generating hyaluronan disaccharides when combined with hyaluronan, and/or the hyaluronan disaccharides themselves, and/or inflammatory hyaluronidase inhibitors. The invention further discloses the use of hyaluronidase inhibitors to treat certain infections in an individual.Type: GrantFiled: April 3, 2014Date of Patent: September 19, 2017Assignee: Cedars-Sinai Medical CenterInventors: George Liu, Pierre Kyme
-
Patent number: 9758438Abstract: The present invention provides novel phosphate-solubilizing fungal strains, compositions comprising novel phosphate-solubilizing fungal strains, and methods of using novel phosphate-solubilizing fungal strains to increase the availability of phosphate for plant uptake in soil. In some embodiments, one or more of the novel phosphate-solubilizing fungal strains is coated onto a seed.Type: GrantFiled: May 13, 2016Date of Patent: September 12, 2017Assignee: NOVOZYMES BIOAG A/SInventors: David Greenshields, Shelagh Steckler, Kari Priest, Caressa Caldwell, Michael Frodyma
-
Patent number: 9738883Abstract: The present invention claims a novel process for the production and purification of microbial collagenase (Microbial Collagenase EC 3.4.24.3) produced by the non-pathogenic aerobic bacterium Vibrio alginolyticus chemovar. iophagus (NCIMB Number: 1 1038, synonym LMG 3418, hereinafter called Vibrio alginolyticus), which said process provides high production levels of collagenase with a stable, reproducible, cheap fermentation process. The collagenase produced from Vibrio alginolyticus according to the process described herein also presents a specific activity superior to that of other microbial collagenases, is stable in aqueous solution, and can be frozen without significant damage.Type: GrantFiled: April 17, 2013Date of Patent: August 22, 2017Assignee: FIDIA FARMACEUTICALS S.P.A.Inventors: Susanna Vaccaro, Michele Caputo, Christian Cuppari, Giovanni Gennari
-
Patent number: 9737591Abstract: Physiologically acceptable anti-biofilm compositions comprising Serratia peptidase and optionally one or more of bromelain, papain and a fibrinolytic enzyme. Additional components can include antimicrobials, antibiotics, antifungals, herbals, chelating agents, lactoferrin and related compounds, minerals, surfactants, binders, and fillers useful for the inhibition and treatment of gastrointestinal biofilms in humans. Physiologically acceptable anti-biofilm compositions containing these enzymes are useful in the inhibition, reduction and/or treatment of biofilms such as in the ear, vagina, joints, bones, gut, surgical sites and other locations, and are useful for the inhibition, reduction and/or treatment of associated systemic symptoms caused by biofilm associated microorganisms.Type: GrantFiled: March 25, 2011Date of Patent: August 22, 2017Assignee: PROTHERA, INC.Inventor: Stephen Francis Olmstead